Emyria expands MDMA programs following landmark TGA decision
Summary
Australia's TGA to designate MDMA and psilocybin Schedule 8 “Controlled Medicines” from July 1st 2023, facilitating access to patients via appropriately qualified Authorised Prescribers [1]
Emyria uniquely positioned to advance and help commercialise MDMA-assisted therapies via:
- Emyria’s established clinical & data infrastructure - can support qualified Authorised Prescribers and therapists deliver MDMA-assisted therapy safely and at-scale
- Real-World Data generation during treatment - can inform care model innovation, drug registration programs, and advance Emyria’s novel, advanced MDMA-inspired drug discovery program with partner the University of Western Australia
A short deck summarising Emyria’s updated strategy accompanies this announcement
Your question will be sent privately to Emyria. The company may choose to make this question public.
Start the conversation
Ask Emyria a question about this announcement.
Share your feedback
Discover